GH Research PLC
NASDAQ:GHRS
8.62 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | GH Research PLC |
Symbool | GHRS |
Munteenheid | USD |
Prijs | 8.62 |
Beurswaarde | 448,482,222 |
Dividendpercentage | 0% |
52-weken bereik | 5.05 - 14.99 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Theis Terwey M.D. |
Website | https://www.ghres.com |
An error occurred while fetching data.
Over GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)